|
Re: 3 point MACE vs 5 point MACE
|
7
|
Resverlogix Corp.
|
Nov 02, 2018 05:50PM
|
|
Re: 3 point MACE vs 5 point MACE
|
4
|
Resverlogix Corp.
|
Nov 02, 2018 10:29PM
|
|
Re: 3 point MACE vs 5 point MACE
|
5
|
Resverlogix Corp.
|
Nov 02, 2018 11:48PM
|
|
Re: MACE event rate
|
4
|
Resverlogix Corp.
|
Nov 03, 2018 04:49PM
|
|
Re: Resverlogix H2 2018 events
|
5
|
Resverlogix Corp.
|
Nov 03, 2018 05:14PM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 03, 2018 11:21PM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 04, 2018 07:57AM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 04, 2018 10:22AM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 05, 2018 11:43AM
|
|
Re: Resverlogix H2 2018 events
|
3
|
Resverlogix Corp.
|
Nov 05, 2018 11:49AM
|
|
BETonMACE baseline data
|
3
|
Resverlogix Corp.
|
Nov 05, 2018 12:11PM
|
|
Re: BIO Europe
|
3
|
Zenith Epigenetics
|
Nov 05, 2018 12:32PM
|
|
BIO-Europe tomorrow
|
2
|
Resverlogix Corp.
|
Nov 05, 2018 12:36PM
|
|
Re: BETonMACE baseline data
|
4
|
Resverlogix Corp.
|
Nov 05, 2018 03:12PM
|
|
Re: BETonMACE baseline data
|
3
|
Resverlogix Corp.
|
Nov 05, 2018 03:19PM
|
|
BET proteins, NFkB and Diabetic Kidney Disease
|
7
|
Resverlogix Corp.
|
Nov 05, 2018 03:54PM
|
|
Re: 3 point MACE in Phase 3 should be 10% percent lower than 4 point MACE in Phase 2's
|
3
|
Resverlogix Corp.
|
Nov 06, 2018 11:09AM
|
|
Re: 3 point MACE in Phase 3 should be 10% percent lower than 4 point MACE in Phase 2's
|
3
|
Resverlogix Corp.
|
Nov 06, 2018 11:19AM
|
|
Re: Bio Europe presentation happening now
|
4
|
Resverlogix Corp.
|
Nov 06, 2018 11:57AM
|
|
Re: Researchers Successfully Treat Metastatic Cancer
|
3
|
Zenith Epigenetics
|
Nov 06, 2018 04:22PM
|
